Chi-Med presents pre-clinical data at ENETS

Hutchison China MediTech Limited presented data from the ongoing phase Ib/II clinical trial of sulfatinib in patients with advanced neuroendocrine tumours at the 14th annual conference of European Neuroendocrine Tumour Society, held in Barcelona from 8-10 March.

At 9:54am: (LON:HCM) Hutchison China Meditech Ltd share price was 0p at 2407.5p

Story provided by